Provided is a controlled-release pharmaceutical composition which contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]- amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, which is a compound of which the solubility in an acidic pH region is extremely different from that in a neutral pH region, as a medicinal agent, wherein the solubility of the medicinal agent can be maintained in a neutral pH region in the digestive tract after gastric emptying (e.g., the small intestine) and the controlled-release pharmaceutical composition exhibits a good oral absorption property and has high bioavailability. The controlled-release pharmaceutical composition comprises 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H- pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, an acidic substance, a persaturation-maintaining agent, and a controlled-release base ingredient.
